In summary, we identified that PD-1/-L1 inhibitor is associated with decreased risk of pruritus and rash in comparison to CTLA-4 inhibitor in both monotherapy and combined immunotherapy regimens. This evidence concerns the gene CTLA4 and Pruritus.